Medical device developer Jeffrey Greiner currently serves as CEO of Valencia Technologies Corporation, a medical technology company that develops and manufactures neuromodulation technologies and products. Greiner takes a keen interest in the potential of neuromodulation to treat a variety of medical conditions and is especially enthusiastic about possible advances in the field of spinal cord stimulation. Greiner formerly led Advanced Bionics as its chief executive officer.
Spinal cord stimulation, a type of neuromodulation, modifies neural activity by delivering mild electrical impulses to nerves along the spinal column via implants. First used to treat back pain in 1967, the therapy was approved by the U.S. Food and Drug Administration in 1989 as a method of relieving neural-related pain in the torso, arms, or legs. Spinal cord stimulation currently accounts for a large percentage of all medical neuromodulation treatments.
Spinal cord stimulation appears to work in two ways: first, by reducing the number of pain signals traveling through the spine, and second, by stimulating spinal nerves to release pain-relieving chemicals. The procedure also improves circulation to the affected region. Increased oxygenation is a potential factor in reducing pain caused by ischemia.
Spinal cord stimulation has proven to be effective in treating pain. In fact, more than 60 percent of candidates who receive the treatment find their pain reduced by 50 to 70 percent, resulting in significant improvement in their quality of life.